5 Big Drugmakers With Important Catalysts in May

5 Big Drugmakers With Important Catalysts in May


Merck anticipates two approval decisions by the U.S. Food and Drug Administration in May. The more important is for Keytruda. An FDA decision on approval of the drug in combination with chemotherapy as a first-line treatment for non-squamous non-small cell lung cancer is expected by May 10. Keytruda already won approval as a monotherapy for first-line treatment of NSCLC.



from Biotech News